key: cord-0262913-ecp9gs6f authors: Consolaro, E.; Suter, F.; Rubis, N.; Pedroni, S.; Moroni, C.; Pasto, E.; Paganini, M. V.; Pravettoni, G.; Cantarelli, U.; Perico, N.; Perna, A.; Peracchi, T.; Ruggenenti, P.; Remuzzi, G. title: A HOME-TREATMENT ALGORITHM BASED ON ANTI-INFLAMMATORY DRUGS TO PREVENT HOSPITALIZATION OF PATIENTS WITH EARLY COVID-19: A MATCHED-COHORT STUDY (COVER 2) date: 2021-10-01 journal: nan DOI: 10.1101/2021.09.29.21264298 sha: fa770c92339ce81e1871d5f10883465b61558a12 doc_id: 262913 cord_uid: ecp9gs6f Background and Aim: While considerable success has been achieved in the management of patients hospitalized with severe coronavirus disease 2019 (COVID-19), far less progress has been made with early outpatient treatment. We assessed whether the implementation of a home treatment algorithm, designed based upon on a pathophysiologic and pharmacologic rationale, during the initial, mild phase of COVID-19, could effectively reduce hospital admissions. Methods: This fully academic, matched-cohort study evaluated outcomes in 108 consecutive consenting patients with mild COVID-19 managed at home by their family doctors from January 2021 to May 2021, according to the proposed treatment algorithm and in 108 age-, sex-, and comorbidities-matched patients who were given other therapeutic schedules (ClinicalTrials.gov: NCT04854824). The primary outcome was COVID-19-related hospitalization. Analyses were by intention-to-treat. Results: One (0.9%) patient in the recommended cohort and 12 (11.1%) in the control cohort were admitted to hospital (P=0.0136). The proposed algorithm reduced, by 85%, the cumulative length of hospital stays (from 141 to 19 days) and related costs (from Euro 60.316 to Euro 9.058). Only 9.8 patients needed to be treated with the recommended algorithm to prevent one hospitalization event. The rate of resolution of major symptoms was numerically, but not significantly, higher in the recommended compared to the control cohort (97.2% versus 93.5%, respectively; P=0.322). Other symptoms lingered in a lower proportion of patients in the recommended than in the control cohort (20.4% versus 63.9%, respectively; P<0.001), and for a shorter period. Conclusion: The adoption of the proposed outpatient treatment algorithm during the early, mild phase of COVID-19 reduced the incidence of subsequent hospitalization and related costs. proposed in the recommendation algorithm. The cohorts were comparable in terms of mean age and 2 0 9 age range, with most subjects aged between 41 and 65 (Table 1) . Females were more prevalent in 2 1 0 both cohorts (57.4% and 64.8%). The concomitant diseases were well distributed between the two 2 1 1 groups, except for overweight/obesity, which were reported in a few more individuals in the 2 1 2 'control' cohort. The most common symptoms at the onset of illness were fever (70.4% vs 72.2%) 2 1 3 and tiredness (68.5% vs 76.9%), followed by cough (60.2% vs 48.2%), and myalgia (48.2% vs 2 1 4 53.7%) in both the 'recommendation' and 'control' cohorts (Table 1 ). More individuals in the 2 1 5 'recommended algorithm' cohort had arthralgia (30.6% vs 3.7%, P=0.001), while ageusia was 2 1 6 significantly more frequent in the 'control' cohort (38.9% vs 55.6%, P=0.020). The distribution of 2 1 7 dyspnea was similar between the two groups (25.9% vs 31.5%, P=0.452). One of the 108 patients (0.9%) in the 'recommended' cohort was hospitalized, compared to 12 of 2 2 1 the 108 patients (11.1%) in the 'control' cohort ( Figure 1 ). The event rate was significantly lower in 2 2 2 the 'recommended' than in the 'control' group (survival analysis for clustered data, P=0.0136) 2 2 3 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted October 1, 2021. ; 1 0 ( Figure 1 ). The patient in the 'recommended' cohort was admitted to hospital due to dyspnea 2 2 4 secondary to interstitial pneumonia (Table 2) . This was the same reason for the hospitalization of all 2 2 5 patients in the 'control' cohort, except for one who was admitted with dyspnea due to documented 2 2 6 pulmonary thromboembolism (Table 2) . To confirm these findings, explorative analysis was performed using the inverse probability 2 2 8 weighting (IPTW) method, including 3368 patients in the control ORIGIN database. We found that 2 2 9 the hospitalization rate in the 'recommended algorithm' cohort was significantly lower than in the 2 3 0 'control' cohort (-0.059; 95% CI, -0.077 to -0.041; P<0.0001). Seventy-four of 108 'recommended' cohort patients were treated with a relatively selective COX-2 2 3 4 inhibitor, such as nimesulide or celecoxib, while 15 patients were given aspirin (Table 3) . Non-2 3 5 adherence to the recommended anti-inflammatory regimen was 24.07%, since 26 patients were 2 3 6 prescribed other NSAIDs (ketoprofen, ibuprofen or paracetamol). In the 'recommended' cohort, anti-inflammatory treatment with NSAIDs was prescribed by family physicians within a mean (± 2 3 8 SD) of 1.7 ± 3.3 days after the onset of symptoms, except for paracetamol that was self- administered by the patients before contacting the doctor. At variance, in the 'control' cohort only 2 4 0 few patients received relatively selective COX-2 inhibitors (n=4) or aspirin (n=5) ( Table 3) . Notably, in this cohort most patients were given paracetamol (n=74), and the remaining ketoprofen 2 4 2 or ibuprofen. Corticosteroids were prescribed to 26% and 6.5% of patients in the 'recommended' and 'control' 2 4 4 cohorts, respectively (P<0.001) (Table 3) . A median of 7 [IQR: 5-8.5] days elapsed between 2 4 5 starting NSAID and corticosteroid prescriptions in the 'recommended' group. More patients were 2 4 6 treated with antibiotics in the 'recommended' than in the 'control' cohort (P=0.039), while 2 4 7 anticoagulants were prescribed in very few cases in both groups (Table 3 ). Ten patients in the 2 4 8 'recommended' cohort and two in the 'control' cohort required oxygen supply at home due to 1 1 decreasing oxygen saturation or following a first episode of dyspnea or wheezing (P=0.033) ( Table 2 5 0 3). Almost all patients achieved resolution of the major symptoms (i.e., complete remission), and the 2 5 2 event rate was numerically -but not significantly -higher in the recommended than in the 'control' 2 5 3 cohort between the two cohorts (P=0.332) (Table 4 ). On the other hand, the proportion of patients with persistent other symptoms, such as anosmia, ageusia/dysgeusia, lack of appetite and fatigue 2 5 5 was significantly lower in the 'recommended' than in the 'control' cohort (20.4% vs 63.9%, 2 5 6 respectively; P<0.001) ( Table 4) . This difference was shown in the subgroups of patients with these 2 5 7 symptoms persisting for 30 to 60 days or more than 60 days (Table 4 ). The single patient in the 'recommended' cohort who was hospitalized was discharged after 19 days, 2 5 9 compared to 12±7 (range, 4 to 26) days in the 12 patients in the 'control' cohort. The cumulative 2 6 0 length of hospital stays in the latter cohort reached 141 days (Table 2) . At variance with the patient 2 6 1 in the 'recommended' cohort who spent 6 days in a sub-intensive care unit and 13 days in the 2 6 2 ordinary unit, none of the patients in the 'control' cohort required admission to sub-intensive care 2 6 3 units or an ICU, and all were managed in the ordinary hospital units (Table 2) . Thus, cumulative 2 6 4 hospitalization costs were €9.058 and €60.316 in the 'recommended' and 'control' cohorts, 2 6 5 respectively ( Figure 2 ). Only 9.8 (95% CI: 6.1 to 25.1) patients needed to be treated with the home 2 6 6 therapy algorithm to prevent one hospitalization event. not the case for the 'control' cohort, in which most patients reported symptoms during the first stage Our recommendation treatment algorithm (17) is based on the idea that it is critical to intervene at severe COVID-19, which would eventually require hospital admission. Indeed, after the initial 3 1 0 exposure to SARS-CoV-2, patients typically develop symptoms that indicate an inflammatory 3 1 1 process within 5 to 6 days on average (15,16), and pro-inflammatory mediators, in particular 3 1 2 cytokines, seem to be integral to the initiation, intensification, propagation and worsening of tissue 3 1 3 morbidity related to 19, 26) . Therefore, our recommended treatment algorithm 3 1 4 moved from this pathophysiologic rationale of early COVID-19 events, and focused on the initial 3 1 5 use of NSAIDs, which has been shown to reduce pro-inflammatory cytokine levels (18). NSAIDs and IL-6) (28) and in hospitalized COVID-19 patients (IL-6) (19,29). The overlap in COX-2 3 2 0 selectivity between coxibs and the more traditional NSAID nimesulide (27) was the rationale for 3 2 1 recommending these drugs for the treatment of early COVID-19 at home, unless contraindicated. Adherence to this recommendation was very high (75.3%) in the 'recommended' algorithm cohort. On the other hand, in the 'control' cohort very few patients were treated with a COX-2 inhibitor, 3 2 4 and most received paracetamol. However, this drug, considered an alternative for addressing the addition to being capable of inducing or worsening glutathione consumption (31,32). Given the 3 2 7 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted October 1, 2021. ; https://doi.org/10.1101/2021.09.29.21264298 doi: medRxiv preprint anti-oxidant property of glutathione, it has recently been hypothesized that paracetamol might even 3 2 8 exacerbate COVID-19 (31,32). Physicians may be reluctant to use NSAIDs, including relatively selective COX-2 inhibitors, due to 3 3 0 the known risk of cardiovascular events (33) and the hepatotoxicity of nimesulide, which is 3 3 1 admittedly very low when the drug is prescribed at the recommended daily dose and time of hospital who had taken NSAIDs within the 2 weeks preceding hospital admission, the use of these 3 3 4 drugs was not associated with higher mortality or increased severity of COVID-19, as compared to COVID-19 patients given NSAIDs compared with those treated with paracetamol, or NSAID non- to or possibly related to the use of celecoxib or nimesulide. This is in line with the fact that few other NSAIDs, such as indomethacin, which also lowers IL-6 in SARS-CoV-2 patients (39), could 3 4 6 be proposed as an alternative treatment for early COVID-19 symptoms at home, as anticipated by a 3 4 7 recent small Indian study (40). The same pharmacologic rationale was adopted for the recommendation of the use of corticosteroids, known to exert their anti-inflammatory effects mainly by inhibiting pro- only starting corticosteroid several days after the onset of symptoms if fever or musculoskeletal 3 5 2 pain persist despite NSAIDs or when oxygen saturation significantly declines. According to this, in 3 5 3 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted October 1, 2021. ; https://doi.org/10.1101/2021.09.29.21264298 doi: medRxiv preprint the 'recommended algorithm' cohort, corticosteroids were administered only after a median of 7 3 5 4 days after the onset of symptoms and when they fulfilled the proposed criteria for starting this class 3 5 5 of drugs, not necessarily limited to patients in need of oxygen supply. This might explain the 3 5 6 discrepancy between the number of patients treated with corticosteroids (n=28) and those given require respiratory support (44). However, there is also some evidence of the benefit of which are similar to those achieved in our 'recommended algorithm' cohort. Interestingly, the antibiotics in 37% of their COVID-19 patients. This is not surprising, considering that in a with antibiotics, despite only 8% presenting with evidence of bacterial coinfection (52). Nonetheless, the risk of developing antimicrobial resistance should invite caution regarding the The non-randomized design is a major limitation of the study, which is observational in nature. Nonetheless, comparative analysis of patient cohorts in everyday clinical practice with adjustments 3 9 6 for possible confounding biases may offer a suitable alternative to the recommended clinical trials 3 9 7 to evaluate the effectiveness of different therapeutic regimens (53,54). Moreover, the matched-3 9 8 cohort study protocol with a statistical plan was predefined and the analyses were performed accordingly. There is the additional limitation that the collection of outcome information in the 4 0 0 'control' cohort was through interviews and questionnaires related to events that happened before 4 0 1 the survey. This was not the case for the 'recommended algorithm' cohort, where data were All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted October 1, 2021. ; 1 7 admission rates for the two cohorts is offered by the results of the additional explorative analysis of 4 0 6 3368 patients in the control ORIGIN database, which confirmed a significantly lower rate of 4 0 7 hospitalization in the 'recommended algorithm' than in the 'control' group. On the other hand, the COVER 2 study formally tested outcomes for COVID-19 patients managed 4 0 9 by their family physicians according to a therapy recommendation algorithm that targets early 4 1 0 symptoms, based on the pathophysiology of the illness and the related pharmacologic rationale. In conclusion, we have documented that simple, reasoned treatments for the early-phase symptoms in clinical practice, since they may avoid or limit deterioration of the disease to the point of All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted October 1, 2021. ; 1 8 We declare that we have no conflicts of interest. The study was partially supported by a generous donation from QuattroR SGR SpA to the Istituto di The COVER 2 study has been approved by the Ethical Committee of Insubria (Varese, Italy; 27 4 4 3 July 2021) and registered at the ClinicalTrials.gov (NCT04854824). In COVER 2, participants in (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted October 1, 2021. revealing participants' identities, as permanent data anonymization was not carried out (patient 4 5 6 records were instead de-identified per protocol during the data retention process). To minimize this 4 5 7 risk, individual participant data that underlie the results reported in this article will be available after Farmacologiche Mario Negri IRCCS. To gain access, data requestors will need to sign a data access 4 6 2 agreement and obtain the approval of the local ethics committee. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted October 1, 2021. for-covid-19-treatments. 13. Available at: https://www.nice.org.uk/guidance/ng165, April 3 2020. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted October 1, 2021. ; https://doi.org/10. 1101 /2021 28. Carey MA, Bradbury JA, Rebolloso YD, Graves JP, Zeldin DC, Germolec DR. Pharmacologic All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted October 1, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted October 1, 2021. ; https://doi.org/10. 1101 /2021 .0043** Data are n/N (percentages) or mean ± SD, as appropriate. * defined as complete recovery from major symptoms, i.e., no fever, SpO 2 >94% and/or no dyspnea, no cough, no rhinitis, no pain (myalgia, arthralgia, chest pain, headache, sore throat), no vertigo, no nausea, vomiting or diarrhea, no sicca syndrome or red eyes; ° defined as recovery from major COVID-19 symptoms, but persistence of symptoms such as anosmia, ageusia/dysgeusia, lack of appetite, fatigue. ** Significant after Bonferroni adjustment for multiple tests. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted October 1, 2021. ; https://doi.org/10. 1101 /2021 Anticoagulants 3 (2.78) 2 (1.85) Amoxicillin and clavulanic acid 0/41 (0)